NEWRON PHARMACEUTICALS S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.71 CHF | +2.00% |
|
-3.67% | +96.16% |
| Sales 2024 * | 36.98M 40.13M 36.68M | Sales 2025 * | 27.02M 29.33M 26.8M | Capitalization | 179M 194M 177M |
|---|---|---|---|---|---|
| Net income 2024 * | 15M 16.28M 14.88M | Net income 2025 * | 5M 5.43M 4.96M | EV / Sales 2024 * | 5.43 x |
| Net Debt 2024 * | 22.05M 23.94M 21.88M | Net cash position 2025 * | 7M 7.6M 6.94M | EV / Sales 2025 * | 6.36 x |
| P/E ratio 2024 * |
11.4
x | P/E ratio 2025 * |
32.7
x | Employees | 22 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
More Fundamentals
* Assessed data
More news
Latest transcript on Newron Pharmaceuticals S.p.A.
More press releases
| 1 day | +2.10% | ||
| 1 week | -3.57% | ||
| Current month | +18.39% | ||
| 1 month | +27.23% | ||
| 3 months | +13.02% | ||
| 6 months | +104.20% | ||
| Current year | +96.36% |
1 week
9.41
10.78
1 month
7.0611.20
Current year
4.5711.45
1 year
3.7011.45
3 years
1.0111.45
5 years
0.9011.45
10 years
0.9035.85
| Managers | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 07-12-31 | |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Ulrich Köstlin
CHM | Chairman | 71 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 9.71 | +2.00% | 30 751 |
| 24-05-24 | 9.52 | -2.66% | 83,190 |
| 24-05-23 | 9.78 | -1.51% | 42,421 |
| 24-05-22 | 9.93 | -1.49% | 62,118 |
| 24-05-21 | 10.08 | -4.91% | 105,295 |
Delayed Quote Swiss Exchange, May 27, 2024 at 09:51 am EDT
More quotes
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinsonâs disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Sector
Pharmaceuticals
Calendar
2024-06-04
- Jefferies Global Healthcare Conference
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.596
EUR
Average target price
14.78
EUR
Spread / Average Target
+53.98%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +96.36% | 194M | |
| -2.10% | 90.02B | |
| -1.18% | 39.15B | |
| -15.83% | 31.71B | |
| +62.80% | 26.47B | |
| -21.68% | 14.34B | |
| -8.73% | 12.89B | |
| -15.05% | 11.18B | |
| -45.69% | 10.97B | |
| +3.67% | 8.94B |
- Stock Market
- Equities
- NWRN Stock
